Af­ter weath­er­ing fail­ure, re­jec­tion and lay­offs, Im­muno­Gen touts a new 'break­through' drug in its come­back plan

While the come­back plan for its lead drug is still up in the air, Im­muno­Gen says it has a sec­ond shot at an an­ti­body-drug con­ju­gate break­through.

The FDA has grant­ed break­through ther­a­py des­ig­na­tion to IMGN632, which tar­gets CD123, in re­lapsed or re­frac­to­ry blas­tic plas­ma­cy­toid den­drit­ic cell neo­plasm. The ag­gres­sive can­cer pri­mar­i­ly af­fects the skin, bone mar­row and lymph nodes.

Hav­ing pre­sent­ed ini­tial da­ta on the first-in-hu­man study at ASH 2019, the biotech said it will re­port up­dates from the dose ex­pan­sion co­hort in De­cem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.